30 • PERINATOLOGY Vol 24 • No. 1 • May–Aug 2023 Husbands of 25 of the 30 women with the hemoglobino- pathy trait agreed for HPLC testing, while 5 husbands refused (acceptance rate 83.33%). Following this test, 7 at-risk couples were identified, and 6 women underwent antenatal diagnosis and 1 woman refused. Of these 6 women who underwent antenatal diagnosis, fetuses of 4 women were found to be homozygous for β-thalassemia, and all the 4 couples opted for pregnancy termination (Figure). IVS-I-5(G>C) mutation with genotype β+/β+ in homozygous state was found in the 4 fetuses.The total direct cost of screening and antenatal diagnosis for the cohort of 615 women was INR 4,47,000 (USD 5415). The cost of prevention of a single β-thalassemia birth came to INR 1,11,750 (USD 1354). Original Article Sampagar A, et al. Feasibility and Cost Analysis of Antenatal Screening and Diagnosis of Hemoglobinopathies Figure. Flow Diagram Showing Antenatal Screening and Diagnosis of Hemoglobinopathies Total no. of women approached for screening 727 No. of women who agreed for testing 615 (84.6%) Women with hemoglobinopathies 30 (4.88%) No. of husbands who refused testing 5 of 25 (16.6%) No. of at-risk couples 7 (28%) No. of antenatal diagnosis done 6 (85.71%) No. of fetuses affected 4 (66.6%) No. of pregnancies terminated 4 (100%) No. of husbands who tested positive 7 of 25 (28%) No. of couples not at risk 18 (72%) Antenatal diagnosis not done 1 (14.28%) No. of fetuses not affected 2 (33.3%) No. of women who refused testing 112 (15.4%) Women without hemoglobinopathies 585 (95.12%)
RkJQdWJsaXNoZXIy MjAwNDg=